StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$80.00+1.06 (+1.34%)

Close on Nov 18, 2026Market cap $7.09BP/E –Yield –

CG Oncology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

CG Oncology's free cash flow for the twelve months ending Sep 30, 2026 was -$189.17M. For fiscal 2025 it was -$132.48M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.48M–
FY2024Dec 31, 2024-$78.95M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$48.82M–
Q2 FY2026Jun 30, 2026-$46.88M–
Q1 FY2026Mar 31, 2026-$57.25M–
Q4 FY2025Dec 31, 2025-$36.22M–
Q3 FY2025Sep 30, 2025-$38.99M–
Q2 FY2025Jun 30, 2025-$27.97M–
Q1 FY2025Mar 31, 2025-$29.29M–
Q4 FY2024Dec 31, 2024-$20.87M–
Q3 FY2024Sep 30, 2024-$15.92M–
Q2 FY2024Jun 30, 2024-$16.13M–
Q1 FY2024Mar 31, 2024-$26.02M–

More CG Oncology figures

See a number that looks wrong?